Metalloproteinases and Recurrent Corneal Erosion Syndrome

Completed

• Conditions: Recurrent Corneal Erosion Syndrome

• Registration Number: NCT02891694
• Lead Sponsor: Fondation Ophtalmologique Adolphe de Rothschild

Brief Summary

Recurrent corneal erosion (RCE) syndrome can be observed either in the context of a dystrophy of the basement membrane or following corneal trauma. This syndrome is characterized by recurrent episodes of ocular pain more or less associated with localized separations between the outer epithelium and the epithelial basal lamina (basement membrane) because of anchorage abnormalities between these two corneal layers. This could be the result of an increased expression of metalloproteinases cleaving the hemidesmosomes which anchor epithelium to the basement membrane.

The investigators hypothesis is that episodes of RCEs are favored by a hyper- expression of matricial metalloprotease 9 (MMP-9) induced by EMMPRIN and Galectin-3. The identification of such induction could lead to development of therapeutics inhibiting EMMPRIN and Galectin- 3 in the RCE syndrome.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2016-08-25
• Study First Submitted QC: 2016-09-06
• Study First Posted: 2016-09-07
• Study Start: 2016-12-02
• Primary Completion: 2020-06-26
• Study Completion: 2020-11-26
• Status Verified: 2020-12
• Last Update Submitted: 2020-12-09
• Last Update Posted: 2020-12-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 19

Inclusion Criteria

• Age > 18 years old
• Recurrent Corneal Erosion Syndrome, with - failure of medical treatment and therapeutic photokeratectomy scheduled
• Photorefractive surgical keratectomy (control patients)

Exclusion Criteria

• Opposition to participation in the study
• Known pregnancy or breast-feeding patient
• No medical insurance coverage

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
expression of the Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) in epithelial cells	baseline

Trial Locations

Locations (1)

Fondation Opthalmologique A de Rothschild; 🇫🇷 Paris, France